Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort.

ABSTRACT:

Background and objective

Benralizumab (Fasenra^™) has recently been approved as add-on maintenance treatment for adult patients with severe eosinophilic asthma inadequately controlled despite high-dosage inhaled corticosteroids plus long-acting β₂-agonists. We aimed to identify and describe the clinical characteristics and disease burden of patients with severe, uncontrolled, eosinophilic asthma in France who may be eligible for treatment with benralizumab.

Patients and methods

This was a retrospective analysis of a prospective, noninterventional, observational study of patients in France enrolled in the Asthma and Bronchial Obstruction Cohort (COBRA). First, we selected adult patients with severe asthma, a documented blood eosinophil count, 12 months of

SUBMITTER: Aubier M 

PROVIDER: S-EPMC6124449 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature